Jefferies Group’s Heron Therapeutics HRTX Stock Holding History

Jefferies Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-292,500	Closed	-$1.67M	–	1682
2022 Q1	$1.67M	Sell	292,500 -234,800	-45%	-$1.72M	0.01%	737
2021 Q4	$4.81M	Buy	+527,300	New	+$5.38M	0.03%	470
2020 Q2	–	Sell	-10,000	Closed	-$117K	–	1637
2020 Q1	$117K	Buy	+10,000	New	+$188K	﹤0.01%	1766
2016 Q2	–	Sell	-68,400	Closed	-$1.3M	–	2264
2016 Q1	$1.3M	Buy	+68,400	New	+$1.35M	0.01%	1031
2015 Q4	–	Sell	-40,000	Closed	-$976K	–	2396
2015 Q3	$976K	Sell	40,000 -5,100	-11%	-$170K	0.01%	1220
2015 Q2	$1.41M	Buy	+45,100	New	+$849K	0.01%	1094

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jefferies Group's HRTX Position: Q2 2022 in Review

Jefferies Group sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 124,545 shares — an estimated $712K sold.

Jefferies Group first reported a position in HRTX in Q4 2017 and held it in 6 quarters. The position peaked at $2.37M in Q4 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Jefferies Group reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Jefferies Group sold 124,545 Heron Therapeutics shares in Q2 2022, an estimated $712K.
Jefferies Group first reported a position in Heron Therapeutics in Q4 2017 and held it in 6 quarters.
Jefferies Group's Heron Therapeutics position peaked at $2.37M in Q4 2021.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.